Trial-Results center  
Clinical trial results database in 100 Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

cardiovascular prevention - hormonal replacement therapy - all type of patients

cardiovascular prevention - hormonal replacement therapy - secondary prevention


Related trials

WISDOM, 2007 - combined estrogen and progestogen vs placebo

EAGAR, 2006 - combined estrogen and progestogen vs placebo

WHISP, 2006 - combined estrogen and progestogen vs placebo

WELL-HART (estrogen alone), 2003 - estrogen vs placebo

WELL-HART (estrogen-progestin), 2003 - combined estrogen and progestogen vs placebo

WHI, 2002 - combined estrogen and progestogen vs placebo

Schulman (NHLBI) (estrogen alone), 2002 - estrogen vs placebo

ESPRIT, 2002 - estrogen vs placebo

Schulman (NHLBI) (estrogen-progestogen), 2002 - combined estrogen and progestogen vs placebo

WAVE, 2002 - combined estrogen and progestogen vs placebo

WEST, 2001 - estrogen vs placebo

EPAT, 2001 - estrogen vs placebo

ERA (estrogen alone ), 2000 - estrogen vs placebo

EVTET, 2000 - combined estrogen and progestogen vs placebo

ERA (estrogen plus medroxyprogesterone), 2000 - combined estrogen and progestogen vs placebo

HERS, 1998 - combined estrogen and progestogen vs placebo

Hall, 1998 - combined estrogen and progestogen vs placebo

PEPI, 1995 - hormonal replacement therapy vs placebo



See also:

  • All cardiovascular prevention clinical trials
  • All clinical trials of hormonal replacement therapy
  • All clinical trials of error
  •  

    HERS II study, 2002

    download pdf: error | hormonal replacement therapy for cardiovascular prevention

    Treatments

    Studied treatment
    Control treatment

    Patients

    Baseline characteristics
    type of prevention (secondary prevention 

    Method and design

    Randomized effectives 1156 / 1165 (studied vs. control)


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    All cause death

    131 / 1156
    116 / 1165
    1,14 [0,90;1,44]

    Non fatal MI

    61 / 1156
    62 / 1165
    0,99 [0,70;1,40]

    Venous thromboembolism

    15 / 1156
    11 / 1165
    classic 1,37 [0,63;2,98]

    cardiovascular events

    228 / 1156
    228 / 1165
    1,01 [0,85;1,19]

    Cardiovascular death

    62 / 1156
    63 / 1165
    0,99 [0,71;1,39]

    stroke (fatal and non fatal)

    59 / 1156
    55 / 1165
    1,08 [0,76;1,55]

    puylmonary embolism

    6 / 1156
    2 / 1165
    classic 3,02 [0,61;14,95]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    All cause death 131 / 1156 (11,3%) 116 / 1165 (10,0%) 1,14 [0,90;1,44]   10510
    Non fatal MI 61 / 1156 (5,3%) 62 / 1165 (5,3%) 0,99 [0,70;1,40]   10510
    Venous thromboembolism 15 / 1156 (1,3%) 11 / 1165 (0,9%) 1,37 [0,63;2,98]   10510
    cardiovascular events 228 / 1156 (19,7%) 228 / 1165 (19,6%) 1,01 [0,85;1,19]   10510
    Cardiovascular death 62 / 1156 (5,4%) 63 / 1165 (5,4%) 0,99 [0,71;1,39]   10510
    stroke (fatal and non fatal) 59 / 1156 (5,1%) 55 / 1165 (4,7%) 1,08 [0,76;1,55]   10510
    puylmonary embolism 6 / 1156 (0,5%) 2 / 1165 (0,2%) 3,02 [0,61;14,95]   10510
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 10510: Gabriel SR, Carmona L, Roque M, Sánchez GL, Bonfill XHormone replacement therapy for preventing cardiovascular disease in post-menopausal women.Cochrane Database Syst Rev 2005;:CD002229

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 11,33% 9,96% 1,4%
    Non fatal MI 5,28% 5,32% -0,5‰
    Venous thromboembolism 1,30% 9,44‰ 3,5‰
    cardiovascular events 19,72% 19,57% 1,5‰
    Cardiovascular death 5,36% 5,41% -0,4‰
    stroke (fatal and non fatal) 5,10% 4,72% 3,8‰
    puylmonary embolism 5,19‰ 1,72‰ 3,5‰

    Meta-analysis of all similar trials:

    hormonal replacement therapy in cardiovascular prevention for all type of patients

    hormonal replacement therapy in cardiovascular prevention for secondary prevention



    Reference(s)

    Trials register # NA
    • Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).. JAMA 2002;288:58-66
      Pubmed | Hubmed | Fulltext
    • Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).. JAMA 2002;288:49-57
      Pubmed | Hubmed | Fulltext

    (c) 2004-2014 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100100